This content was funded by Sanofi.
Watch Thierry Facon highlight the Phase III IMROZ study: a global, randomised, Phase III, open-label study evaluating the efficacy and safety of isatuximab (Isa) delivered in combination with the standard of care VRd (triplet combination of bortezomib, lenalidomide, and dexamethasone). Specifically Isa-VRd induction followed by Isa-Rd (isatuximab, lenalidomide, and dexamethasone) continuous therapy is compared to VRd induction followed by Rd (lenalidomide and dexamethasone) continuous therapy in patients with newly diagnosed multiple myeloma not intended for transplant.
The IMROZ regimen Isa-VRd, followed by Isa-Rd, led to:
- a statistically significant improvement in progression-free survival at a median follow-up of 5 years;
- deep response rates with statistically significant improvements in complete response and minimal-residual disease (MRD), and complete remission rates;
- improvement in MRD and sustained MRD; and
- Isa-VRd being well-tolerated, and the safety profile remaining consistent with the known safety profiles of individual agents.
Speaker
Thierry Facon
Department of Haematology, University of Lille, and French Academy of Medicine, Paris, France
